JPWO2020160010A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160010A5 JPWO2020160010A5 JP2021543157A JP2021543157A JPWO2020160010A5 JP WO2020160010 A5 JPWO2020160010 A5 JP WO2020160010A5 JP 2021543157 A JP2021543157 A JP 2021543157A JP 2021543157 A JP2021543157 A JP 2021543157A JP WO2020160010 A5 JPWO2020160010 A5 JP WO2020160010A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 150000003839 salts Chemical class 0.000 claims 39
- 239000011780 sodium chloride Substances 0.000 claims 39
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000000547 substituted alkyl group Chemical group 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical group 0.000 claims 13
- -1 3 -hydroxycyclobutyl Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000003107 substituted aryl group Chemical group 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004432 carbon atoms Chemical group C* 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 6
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 5
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 5
- 208000008425 Protein Deficiency Diseases 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 101700084127 AVP Proteins 0.000 claims 4
- 102100017238 AVP Human genes 0.000 claims 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims 4
- 201000010064 diabetes insipidus Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 102100004109 HEY1 Human genes 0.000 claims 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 235000013921 calcium diglutamate Nutrition 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 201000003883 cystic fibrosis Diseases 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000004622 Abetalipoproteinemia Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010006451 Bronchitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 101700028745 CR17 Proteins 0.000 claims 1
- 210000003591 Cerebellar Nuclei Anatomy 0.000 claims 1
- 201000011470 Charcot-Marie-Tooth disease Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000007451 Chronic Bronchitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000005603 Fabry disease Diseases 0.000 claims 1
- 208000005139 Hereditary Angioedema Types I and II Diseases 0.000 claims 1
- 206010057873 Hereditary haemochromatosis Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 102100012475 LDLR Human genes 0.000 claims 1
- 108060004326 LDLR Proteins 0.000 claims 1
- 208000006302 Laron Syndrome Diseases 0.000 claims 1
- 208000009856 Lung Disease Diseases 0.000 claims 1
- 206010024579 Lysosomal storage disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028093 Mucopolysaccharidosis Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidosis Diseases 0.000 claims 1
- 208000000638 Myeloperoxidase Deficiency Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000009025 Nervous System Disease Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 206010029305 Neurological disorder Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 206010033628 Pancreatic insufficiency Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000011585 Pick's disease Diseases 0.000 claims 1
- 208000009901 Polycystic Kidney Disease Diseases 0.000 claims 1
- 208000003055 Prion Disease Diseases 0.000 claims 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 claims 1
- 210000000463 Red Nucleus Anatomy 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 210000001177 Vas Deferens Anatomy 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 125000005002 aryl methyl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000002146 bilateral Effects 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 230000020764 fibrinolysis Effects 0.000 claims 1
- 230000003480 fibrinolytic Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 201000011240 frontotemporal dementia Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 230000003451 hyperinsulinaemic Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 201000010136 inclusion-cell disease Diseases 0.000 claims 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 230000000510 mucolytic Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002988 nephrogenic Effects 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000005660 protein C deficiency Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962797743P | 2019-01-28 | 2019-01-28 | |
US62/797,743 | 2019-01-28 | ||
US201962931502P | 2019-11-06 | 2019-11-06 | |
US62/931,502 | 2019-11-06 | ||
PCT/US2020/015441 WO2020160010A1 (fr) | 2019-01-28 | 2020-01-28 | Composés et méthodes pour le traitement de la fibrose kystique |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022518778A JP2022518778A (ja) | 2022-03-16 |
JPWO2020160010A5 true JPWO2020160010A5 (fr) | 2023-02-01 |
Family
ID=71841934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021543157A Pending JP2022518778A (ja) | 2019-01-28 | 2020-01-28 | 嚢胞性線維症の治療のための化合物および方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230055237A1 (fr) |
EP (1) | EP3917516A4 (fr) |
JP (1) | JP2022518778A (fr) |
CN (1) | CN113613649A (fr) |
WO (1) | WO2020160010A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
EP4029500A1 (fr) * | 2021-01-15 | 2022-07-20 | Universidad Autónoma de Madrid | Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibiteurs de l'interaction nrf2-beta-trcp pour le traitement des maladies liées au nrf2 |
RU2763141C1 (ru) * | 2021-06-29 | 2021-12-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Этил (3r*,3a'r*,8a'r*,8b's*)-1',2,3'-триоксо-2',5-дифенил-1-(4-хлорфенил)-1,2,2',3',3a',6',7',8',8a',8b'-декагидро-1'h-спиро[пиррол-3,4'-пирроло[3,4-a]пирролизин]-4-карбоксилат, обладающий противомикробной активностью |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008334629B2 (en) * | 2007-12-10 | 2012-04-12 | Novartis Ag | Organic compounds |
US11174267B2 (en) * | 2015-06-12 | 2021-11-16 | The Regents Of The University Of California | Spiroindolinones and therapeutic uses thereof |
US10072017B2 (en) * | 2015-12-30 | 2018-09-11 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
-
2020
- 2020-01-28 EP EP20747868.6A patent/EP3917516A4/fr active Pending
- 2020-01-28 CN CN202080018339.8A patent/CN113613649A/zh active Pending
- 2020-01-28 WO PCT/US2020/015441 patent/WO2020160010A1/fr unknown
- 2020-01-28 JP JP2021543157A patent/JP2022518778A/ja active Pending
-
2021
- 2021-07-23 US US17/383,797 patent/US20230055237A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ746793A (en) | Silicone atoms containing ivacaftor analogues | |
CN111848616B (zh) | 吡啶酮衍生物及其用于制备抗流感病毒药物的用途 | |
CA3041675A1 (fr) | Derives n-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazine-1-yl)acetamide pour traiter la mucoviscidose | |
CN110372672B (zh) | 含酰肼的核运输调节剂及其用途 | |
AU2019213211B2 (en) | Compounds | |
WO2018081378A1 (fr) | Composés, compositions et méthodes permettant de moduler cftr | |
RU2010114732A (ru) | Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида | |
CA3078230A1 (fr) | Composes, compositions et methodes pour augmenter l'activite de cftr | |
RU2017126232A (ru) | Соединения, композиции и способы для повышения активности cftr | |
SI3091011T1 (en) | Modulators of ATP conveyor belt conveyors | |
TW201726606A (zh) | 作為免疫調節劑之化合物 | |
EP3532467A1 (fr) | Composés de pyridazine, compositions et méthodes permettant de moduler cftr | |
JP2010528050A5 (fr) | ||
HRP20151141T1 (hr) | Derivati piridila kao modulatori cftr | |
JP6980014B2 (ja) | ENaC阻害剤としてのベンゾジアゾリウム化合物 | |
CZ36699A3 (cs) | Muskarinní antagonisté | |
US20070270470A1 (en) | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid cb1 receptor antagonists | |
HRP20170572T1 (hr) | Derivati pirazina kao agonisti receptora cb2 | |
BR112020014516A2 (pt) | Aminopirrolotriazinas como inibidores de quinase | |
JP7333793B2 (ja) | 化合物 | |
CN115916748A (zh) | 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的吲哚衍生物 | |
JPWO2020160010A5 (fr) | ||
CN111303147A (zh) | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 | |
CN114269721A (zh) | 用于治疗呼吸系统疾病的化合物 | |
RU2796112C2 (ru) | Кремнийсодержащие аналоги ивакафтора |